A Phase 1a, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of DT-216 in Adult Patients With Friedreich Ataxia
Latest Information Update: 30 Jun 2023
At a glance
- Drugs DT-216 (Primary)
- Indications Friedreich's ataxia
- Focus Adverse reactions
- Sponsors Design Therapeutics
- 07 Dec 2022 According to a Design Therapeutics media release, the company will host a live webcast and conference call to discuss updates from the SAD and MAD trials.
- 07 Dec 2022 Results published in a Design Therapeutics media release.
- 08 Aug 2022 According to a Design Therapeutics media release, Initial Data from this trial of DT-216 Expected in the Fourth Quarter of 2022